mmda-2 mmda-2 mmda-2 (2-methoxy-4,5-methylenedioxyamphetamine) is a psychedelic drug of the amphetamine class. it is closely related to mmda and mda. mmda-2clinical dataroutes ofadministrationoral, insufflated, rectalatc codenonelegal statuslegal status ca: schedule i de: npsg (industrial and scientific use only) uk: class a uncontrolled (but may be covered under the federal analogue act in the united states and under similar bills in other countries) identifiers iupac name 1-(6-methoxy-1,3-benzodioxol-5-yl)propan-2-amine cas number23693-18-7pubchem cid90966chemspider82147uniitg0b6er184comptox dashboard (epa)dtxsid20903968 chemical and physical dataformulac11h15no3molar mass209.245 g·mol−13d model (jsmol)interactive image smiles o1c2cc(c(oc)cc2oc1)cc(n)c alexander shulgin was likely the first to synthesize mmda-2. in his book pihkal, the dose is listed as 25–50 mg, and the duration is listed as 8–12 hours. shulgin reports that mmda-2 produces effects such as enhanced awareness, empathy, and visual facilitation and distortion, as well as some side effects like gastrointestinal upset and appetite loss. he states that 30 mg is very similar to 80 mg of mda, and also remarks that it would be impossible for anyone to have a bad experience on the drug at that dose. scientific research has shown that mmda-2, unlike mmda, but similarly to 6-methyl-mda, is only very weak at inducing the release of serotonin or dopamine, and accordingly, does not produce amphetamine-like responses in animals in drug discrimination studies. instead, mmda-2 is likely to act as a pure 5-ht2 receptor agonist similarly to the dox series of compounds, with activation of the 5-ht2a receptor conferring its psychedelic effects. mmda-2 has been sold as a designer drug in japan.